From Breakthroughs to Blueprints: Evolving Evidence and Future Directions in Relapsed and Refractory Large B-Cell Lymphoma

The authors examine the evolving treatment landscape for relapsed or refractory large B-cell lymphoma (R/R LBCL) in light of recent advancements in cellular therapies, bispecific antibodies, and next-generation antibody-drug conjugates. They aim to address the challenges posed by trial design and therapeutic sequencing, emphasizing the need for improved evidence infrastructure and biologically rational treatment pathways to ensure equitable access to effective therapies for all patients. The paper highlights the urgency of adapting clinical trials to keep pace with rapid innovations in treatment options.